Dr. Greg Parekh is the founder of New Rhein and is a board member and advisor to the American Society of Clinical Oncology (ASCO). He served as CEO of Biocartis NV, a Belgian oncology diagnostics company from 2011 to 2013.
Prior to Biocartis, Greg ran M&A for Novartis (2004 to 2009) and led the Alcon integration planning (2010). While at Novartis, he helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to Novartis, Greg headed Deutsche Bank’s European healthcare group. He has over ten years of investment banking experience in NY and London, mostly in pharmaceuticals and biotechnology.
He holds a Ph.D. in Economics from Northwestern University. He is married with four children. His hobbies include DJing at clubs & festivals, downhill skiing and gourmet cooking.